SELECT: Semaglutide Reduces CV Events and Diabetes Risk

Two new analyses of the SELECT trial show that the GLP-1 receptor agonist improves cardiovascular health and reduces or normalizes glycemic levels irrespective of baseline A1c.
Medscape Medical News

source https://www.medscape.com/viewarticle/select-semaglutide-reduces-cv-events-and-diabetes-risk-2024a1000bma?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost